These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26328056)

  • 1. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial.
    Klimek L; Bachert C; Lukat KF; Pfaar O; Meyer H; Narkus A
    Clin Transl Allergy; 2015; 5():28. PubMed ID: 26328056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.
    Campana R; Moritz K; Marth K; Neubauer A; Huber H; Henning R; Blatt K; Hoermann G; Brodie TM; Kaider A; Valent P; Sallusto F; Wöhrl S; Valenta R
    J Allergy Clin Immunol; 2016 Feb; 137(2):601-609.e8. PubMed ID: 26518092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
    Treudler R; Franke A; Schmiedeknecht A; Ballmer-Weber B; Worm M; Werfel T; Jappe U; Biedermann T; Schmitt J; Brehler R; Kleinheinz A; Kleine-Tebbe J; Brüning H; Ruëff F; Ring J; Saloga J; Schäkel K; Holzhauser T; Vieths S; Simon JC
    Allergy; 2017 Aug; 72(8):1243-1253. PubMed ID: 27998002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
    Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
    Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
    van Hage-Hamsten M; Johansson E; Roquet A; Peterson C; Andersson M; Greiff L; Vrtala S; Valenta R; Grönneberg R
    Clin Exp Allergy; 2002 Oct; 32(10):1448-53. PubMed ID: 12372124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
    Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
    J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
    Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
    Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen.
    Seutter von Loetzen C; Reuter A; Spiric J; Schulenborg T; Bellinghausen I; Völker E; Vogel L; Rösch P; Schiller D
    Clin Exp Allergy; 2019 May; 49(5):712-723. PubMed ID: 30706562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen.
    Grönlund H; Gafvelin G
    Hum Vaccin; 2010 Dec; 6(12):970-7. PubMed ID: 21157177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy.
    Sánchez Acosta G; Kinaciyan T; Kitzmüller C; Möbs C; Pfützner W; Bohle B
    J Allergy Clin Immunol; 2020 Oct; 146(4):894-900.e2. PubMed ID: 32259540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen.
    Arquint O; Helbling A; Crameri R; Ferreira F; Breitenbach M; Pichler WJ
    J Allergy Clin Immunol; 1999 Dec; 104(6):1239-43. PubMed ID: 10589007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations.
    Niederberger V; Pauli G; Grönlund H; Fröschl R; Rumpold H; Kraft D; Valenta R; Spitzauer S
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):579-91. PubMed ID: 9802365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.